1. Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade
- Author
-
Douglas B. Fox, Richard Y. Ebright, Xin Hong, Hunter C. Russell, Hongshan Guo, Thomas J. LaSalle, Ben S. Wittner, Nicolas Poux, Joanna A. Vuille, Mehmet Toner, Nir Hacohen, Genevieve M. Boland, Debattama R. Sen, Ryan J. Sullivan, Shyamala Maheswaran, and Daniel A. Haber
- Subjects
Cancer Research ,Oncology - Abstract
Immune checkpoint blockade (ICB) has demonstrated efficacy in patients with melanoma, but many exhibit poor responses. Using single cell RNA sequencing of melanoma patient-derived circulating tumor cells (CTCs) and functional characterization using mouse melanoma models, we show that the KEAP1/NRF2 pathway modulates sensitivity to ICB, independently of tumorigenesis. The NRF2 negative regulator, KEAP1, shows intrinsic variation in expression, leading to tumor heterogeneity and subclonal resistance.
- Published
- 2023
- Full Text
- View/download PDF